Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2
Authors:
- Hajime NakamuraHNHajime Nakamura
- Hiroshi MasutaniHMHiroshi Masutani
- Junji YodoiJYJunji Yodoi
- 1 September 2010
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 127 (3) , 261-270
Abstract
No abstract availableKeywords
This publication has 120 references indexed in Scilit:
- Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditionsJournal of Cellular Physiology, 2009
- Dendritic cells derived from TBP‐2‐deficient mice are defective in inducing T cell responsesEuropean Journal of Immunology, 2008
- Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitusJournal of Cellular Physiology, 2007
- Thioredoxin in the cardiovascular systemJournal of Molecular Medicine, 2006
- Thioredoxin interacting protein in Dutch families with familial combined hyperlipidemiaAmerican Journal of Medical Genetics Part A, 2004
- Identification of a novel thioredoxin‐related protein, PC‐TRP, which is preferentially expressed in plasma cellsEuropean Journal of Immunology, 2003
- Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductaseJournal of Molecular Biology, 1998
- Early Embryonic Lethality Caused by Targeted Disruption of the Mouse Thioredoxin GeneDevelopmental Biology, 1996
- Expression and growth-promoting effect of adult t-cell leukemia-derived factor a human thioredoxin homologue in hepatocellular carcinomaCancer, 1992
- ATL‐derived factor (ADF), an IL‐2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol‐reduction in the IL‐2 receptor induction.The EMBO Journal, 1989